BOCA RATON, Fla., April 4, 2011 /PRNewswire/ — Breckenridge is
announcing that it entered into an agreement with Oman
Pharmaceutical Products Company LLC, of Salalah, Sultanate of Oman
to market Neomycin Sulfate Tablets. Under the terms of the
agreement, the product will be manufactured by Oman Pharma, and
marketed and distributed by Breckenridge on an exclusive basis in
the United States. The ANDA has been approved by the U.S. Food and
Drug Administration (FDA), and the companies began shipping the
product at the start of 2011.
About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held
pharmaceutical marketing, research and development company founded
in 1983 that markets a broad range of generic prescription products
in many therapeutic categories. The Breckenridge label is
recognized by Wholesalers, Distributors, Chains, and Managed Care
Accounts, as well as Retail Pharmacies nationwide. The company
markets over 70 products in a variety of dosage forms including:
Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and
Powders.
About Oman:
Oman Pharmaceutical Products Co. L.L.C. (OPP) is a Global
Pharmaceutical company specializing in the development, production
& marketing of generic and OTC pharmaceuticals in the GCC and
world-wide. The ultramodern plant of Oman Pharmaceutical Products
Co. LLC is located in Salalah, South of Oman. The manufacturing
plants are approved by U.S. Food and Drug Administration (FDA), UK
MHRA, Australian TGA, German Authorities and the GCC health
authorities and are regularly inspected by these Health
Authorities. www.omanpharma.com
‘/>”/>
SOURCE
